Clinical Trials Logo

Clinical Trial Summary

Patients with cancer are more likely than those without cancer to develop blood clots (deep vein thrombosis and pulmonary embolism), which are treated using blood thinners (anticoagulants). When clots occur, cancer patients carry a higher risk of recurring clots and more likely to bleed on blood thinning treatments. Therefore, it is critical to use blood thinners that optimize the safety and benefits. There are two main types of blood thinners that are recommended. The tablets which are direct-acting oral anticoagulants and the injections (low molecular-weight heparin). Clinical trials show the tablets may reduce clot risk but may potentially lead to more frequent bleeding, particularly in those with certain risk factors such as stomach ulcers, previous bleeding problems, certain cancer type. We aim to examine the effectiveness and safety of the tablets versus the injections for treatment of clots in cancer patients, to better understand these treatments' benefits and risks.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05112666
Study type Observational
Source Bayer
Contact Bayer Clinical Trials Contact
Phone (+)1-888-84 22937
Email [email protected]
Status Not yet recruiting
Start date November 10, 2021
Completion date July 31, 2022